Why Mirati Therapeutics Is A Dangerous Rival To Amgen In Colon Cancer - (Investor's Business Daily via NewsPoints Desk)

  • SVB Leerink analyst Andrew Berens said on Monday that Mirati Therapeutics could beat Amgen to market with a KRAS-blocking colon cancer drug, Investor's Business Daily

  • Mirati said 22% of patients with colon cancer responded to treatment with its drug adagrasib.

  • The results likely surpass what the FDA would require for accelerated approval, according to Berens said.

  • "We believe that there is likely to be an accelerated pathway available to monotherapy adagrasib, unlike [Amgen's drug] Lumakras, which will likely allow adagrasib to get first-mover advantage in colorectal cancer," he said.

  • When Mirati tested adagrasib in combination with Eli Lilly's Erbitux (cetuximab) that targets the EGFR receptor, the combination led to an overall response rate of 43%.

  • "We think a first-mover advantage in colorectal cancer could be difficult to displace and could allow access to off-label usage in earlier lines of therapy, given that EGFR inhibitors are already commercially available," he said.

To read more NewsPoints articles, click here.

Reference Articles